SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-ADC Therapeutics Announces Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine In Relapsed Or Refractory Hodgkin Lymphoma

reuters.com · 06/10/2022 03:04
BRIEF-ADC Therapeutics Announces Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine In Relapsed Or Refractory Hodgkin Lymphoma

- ADC Therapeutics SA ADCT:

  • ADC THERAPEUTICS ANNOUNCES RESULTS FROM PIVOTAL PHASE 2 CLINICAL TRIAL OF CAMIDANLUMAB TESIRINE (CAMI) IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

  • OVERALL RESPONSE RATE OF 70.1% AND COMPLETE RESPONSE RATE OF 33.3% IN HEAVILY PRETREATED PATIENTS

  • PREPARING FOR POTENTIAL SUBMISSION OF A BIOLOGICS LICENSE APPLICATION TO THE FDA

  • SAFETY PROFILE SUBSTANTIALLY CONSISTENT WITH PRIOR FINDINGS

Source text for Eikon: ID:nBwKRgcXa

Further company coverage: ADCT


((Reuters.briefs@thomsonreuters.com;))